SCHEMBL4123129

SCHEMBL4123129

CCCOc1ccc(NC(=O)Nc2cccc(CC)c2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.59
MAPK14 Q16539 2/20 0.59
TNNI3K Q59H18 1/20 0.59
SMN1; SMN2 Q16637 6/20 0.59
RAB9A P51151 5/20 0.59
MEN1 O00255 5/20 0.59
KMT2A Q03164 5/20 0.59
MAPT P10636 5/20 0.59
NPC1 O15118 4/20 0.59
MITF O75030 1/20 0.56
PAX8 Q06710 1/20 0.56
GAA P10253 1/20 0.54
ALOX15 P16050 1/20 0.54
TP53 P04637 2/20 0.51
TSHR P16473 1/20 0.51
EPHX2 P34913 1/20 0.51
PPARA Q07869 1/20 0.51
CA12 O43570 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4117508 0.89 MAPT (0.70) KDRMAPK14TNNI3KSMN1; SMN2RAB9A
SCHEMBL4113719 0.86 EPHX2 (0.59) SMN1; SMN2RAB9AMEN1KMT2AMAPT
SCHEMBL4112924 0.85 SAE1 (0.62) KDRTNNI3KSMN1; SMN2RAB9AMEN1
SCHEMBL4124694 0.85 MAPT (0.75) KDRMAPK14TNNI3KSMN1; SMN2RAB9A
SCHEMBL4104949 0.84 PPARA (0.68) SMN1; SMN2RAB9AMAPTNPC1MITF
SCHEMBL4118335 0.84 MAPT (0.67) SMN1; SMN2RAB9AMEN1KMT2AMAPT
SCHEMBL4115679 0.84 TSHR (0.74) SMN1; SMN2RAB9AMEN1KMT2AMAPT
SCHEMBL4105865 0.84 RAB9A (0.67) SMN1; SMN2RAB9AMEN1KMT2AMAPT
SCHEMBL4106089 0.84 MEN1 (0.60) KDRSMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL4115459 0.84 KDR (0.56) KDRMAPK14TNNI3KSMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US claimed
EP-1804785-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2007-07-11 EP claimed
WO-2006049941-A2 DIARYL UREAS AS CB1 ANTAGONISTS NEUROGEN CORPORATION (US) 2006-05-11 WO claimed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists NEUROGEN CORPORATION 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239841-A1 Diaryl Ureas as CB1 Antagonists CNR1, CNR2, OPRL1 KDR 3246/4885MAPK14 3162/4885TNNI3K 4016/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.